Biomarin Pharmaceutical Inc at Canaccord Genuity Growth Conference (Virtual) Transcript
Hello, everyone. Good afternoon, and thank you for joining us today. My name is Michelle Gilson. I'm one of the biotech analysts here at Canaccord Genuity. I'm super excited to welcome Hank Fuchs, the President of Worldwide Research and Development; and Brian Mueller, Chief Financial Officer, here from BioMarin, today for a fireside chat. To start us off, I am going to pass it off to Brian for some opening remarks.
Thanks, Michelle. We appreciate the opportunity to participate in your virtual conference. 2020 is truly a transformational year for BioMarin. For the first time in our history, we expect for the profitable for the full year of a GAAP basis despite the challenges brought about by COVID-19. We've positioned ourselves well to drive significant growth beyond our established base business with the potential additions of both ROCTAVIAN gene therapy for hemophilia A and vosoritide for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
